A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die. Every participant takes nerandomilast as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study. Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests.

NCT Number	NCT06238622
Lead Sponsor	Boehringer Ingelheim
Conditions	Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Enrollment	1,700 participants
Start Date	2024-05-06
Primary Completion	2027-04-28 (estimated)
Study Completion	2027-05-05 (estimated)
Updated on ClinicalTrials.gov	2026-08-06